AU2016308105B2 - Quantitative peri-orbital application of ophthalmology drugs - Google Patents

Quantitative peri-orbital application of ophthalmology drugs Download PDF

Info

Publication number
AU2016308105B2
AU2016308105B2 AU2016308105A AU2016308105A AU2016308105B2 AU 2016308105 B2 AU2016308105 B2 AU 2016308105B2 AU 2016308105 A AU2016308105 A AU 2016308105A AU 2016308105 A AU2016308105 A AU 2016308105A AU 2016308105 B2 AU2016308105 B2 AU 2016308105B2
Authority
AU
Australia
Prior art keywords
composition
patient
eye
fluorobiphenyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016308105A
Other languages
English (en)
Other versions
AU2016308105A1 (en
Inventor
Weizhen Wang
David Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenivision Inc
Original Assignee
Jenivision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenivision Inc filed Critical Jenivision Inc
Publication of AU2016308105A1 publication Critical patent/AU2016308105A1/en
Application granted granted Critical
Publication of AU2016308105B2 publication Critical patent/AU2016308105B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
AU2016308105A 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs Ceased AU2016308105B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/829,789 US9820954B2 (en) 2015-08-19 2015-08-19 Quantitative peri-orbital application of ophthalmology drugs
US14/829,789 2015-08-19
PCT/US2016/047230 WO2017031137A1 (en) 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs

Publications (2)

Publication Number Publication Date
AU2016308105A1 AU2016308105A1 (en) 2018-02-15
AU2016308105B2 true AU2016308105B2 (en) 2021-05-27

Family

ID=58051248

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016308105A Ceased AU2016308105B2 (en) 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs

Country Status (9)

Country Link
US (1) US9820954B2 (enExample)
EP (1) EP3337474A4 (enExample)
JP (1) JP6924429B2 (enExample)
KR (1) KR102685479B1 (enExample)
CN (1) CN108135873A (enExample)
AU (1) AU2016308105B2 (enExample)
CA (1) CA2992483C (enExample)
MX (1) MX391627B (enExample)
WO (1) WO2017031137A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827225B2 (en) 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
WO2019005139A1 (en) * 2017-06-30 2019-01-03 Jenivision Inc. FORMULATIONS FOR HAIR GROWTH
GB2597731A (en) * 2020-07-31 2022-02-09 Imperial College Innovations Ltd Preterm labour
JP2024506872A (ja) * 2021-02-05 2024-02-15 ジェニヴィジョン インク． Ｅｐ２受容体アゴニストの眼窩周囲投与のための組成物および方法
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases
CN116869991A (zh) * 2023-06-06 2023-10-13 南昌大学 柚皮素在制备治疗和/或预防眼部疾病的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318422A1 (en) * 2006-08-28 2009-12-24 Akiharu Isowaki Ophthalmic percutaneous absorption type preparation
US7803841B2 (en) * 2004-02-12 2010-09-28 Asterand Uk Limited EP2 receptor agonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3990444A (en) 1972-11-22 1976-11-09 Vial S.A.R.L. Blood transfusion apparatus
US4131115A (en) 1976-09-20 1978-12-26 Peng Sung S Eyelids-turning and eye-washing fixture
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
ATE109970T1 (de) 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
JP2007534384A (ja) 2004-04-23 2007-11-29 ミスティック ファーマシューティカルズ， インコーポレイテッド 複数の単位用量の薬物送達システム
US7226435B2 (en) 2004-10-14 2007-06-05 Alcon, Inc. Drug delivery device
AU2006254825A1 (en) * 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
US20070016256A1 (en) 2005-07-18 2007-01-18 Korb Donald R Method and apparatus for treating gland dysfunction
WO2007095486A1 (en) 2006-02-13 2007-08-23 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
CA2650592A1 (en) 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
AU2007313684A1 (en) * 2006-10-31 2008-05-08 Alcon Research, Ltd. PAI-1 binding modulators for the treatment of ocular disorders
DK2173407T3 (da) 2007-07-02 2020-04-27 Hoffmann La Roche Anordning til indgivelse af lægemiddel
TW200927169A (en) * 2007-11-07 2009-07-01 Alcon Res Ltd Complement Clq inhibitors for the prevention and treatment of glaucoma
MX2010005012A (es) 2007-11-08 2010-06-23 Aciex Therapeutics Inc Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
MX2010008226A (es) * 2008-02-05 2010-10-25 Asterand Uk Ltd Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP2493475A4 (en) 2009-10-30 2014-10-29 Intratus Inc COSMETIC METHODS AND PREPARATIONS FOR THE PROLONGED RELEASE OF THERAPEUTIC AGENTS IN THE EYE
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
EP2544757A4 (en) 2010-03-09 2013-11-06 Toxcure Inc MICRONADEL DEVICE FOR NASAL DISTRIBUTION
US9199066B2 (en) 2010-03-12 2015-12-01 Quattro Vascular Pte Ltd. Device and method for compartmental vessel treatment
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
GB2482691B (en) 2010-08-10 2013-08-14 Nemaura Pharma Ltd Structures for transdermal drug delivery
US8900626B2 (en) 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
JP2014530177A (ja) * 2011-09-16 2014-11-17 フオベア・フアルマシユテイカル アニリン誘導体、それらの調製およびそれらの治療適用
AU2012339695B2 (en) 2011-11-15 2017-10-05 Allergan, Inc. Sustained action formulation of cyclosporin Form 2
WO2014045300A2 (en) 2012-09-03 2014-03-27 Fdc Limited "topical drug delivery system"
CN203379477U (zh) 2012-12-14 2014-01-08 上海市第七人民医院 一种微针滚轮装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803841B2 (en) * 2004-02-12 2010-09-28 Asterand Uk Limited EP2 receptor agonists
US20090318422A1 (en) * 2006-08-28 2009-12-24 Akiharu Isowaki Ophthalmic percutaneous absorption type preparation

Also Published As

Publication number Publication date
KR20180042348A (ko) 2018-04-25
CA2992483A1 (en) 2017-02-23
AU2016308105A1 (en) 2018-02-15
CN108135873A (zh) 2018-06-08
US20170049734A1 (en) 2017-02-23
CA2992483C (en) 2024-03-19
EP3337474A1 (en) 2018-06-27
MX2018001918A (es) 2018-11-09
JP6924429B2 (ja) 2021-08-25
WO2017031137A1 (en) 2017-02-23
MX391627B (es) 2025-03-21
JP2018528169A (ja) 2018-09-27
EP3337474A4 (en) 2019-04-10
KR102685479B1 (ko) 2024-07-15
US9820954B2 (en) 2017-11-21

Similar Documents

Publication Publication Date Title
AU2016308105B2 (en) Quantitative peri-orbital application of ophthalmology drugs
CA2880027C (en) Progesterone compositions and treatment for eye diseases and disorders
US10792288B2 (en) Preservative free brimonidine and timolol solutions
US20090318549A1 (en) Combination treatment of glaucoma
CN111867560B (zh) 包含噻吗洛尔的药物组合物
SG186361A1 (en) Polymeric system for delivering a preservative-free prostaglandin-based nonviscous solution
US11857537B2 (en) Use of prostacyclin antagonists for treating ocular surface nociception
TWI852041B (zh) 採用長春西汀治療近視的方法
CN117062602A (zh) 用于ep2受体激动剂的眶周施用的组合物和方法
EP1951229B1 (en) Succinimide derivatives as ocular hypotensive agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired